超声与触诊引导皮质类固醇注射治疗德-夸尔曼病:随机对照试验

Pm & R Pub Date : 2024-04-22 DOI:10.1002/pmrj.13144
Ying‐Chen Kuo, Lin‐Fen Hsieh, Ya‐Fang Liu, Chia‐Sung Chang
{"title":"超声与触诊引导皮质类固醇注射治疗德-夸尔曼病:随机对照试验","authors":"Ying‐Chen Kuo, Lin‐Fen Hsieh, Ya‐Fang Liu, Chia‐Sung Chang","doi":"10.1002/pmrj.13144","DOIUrl":null,"url":null,"abstract":"IntroductionCorticosteroid injection effectively treats de Quervain disease, and due to the high prevalence of the intracompartmental septum in the first extensor compartment, ultrasound guidance improves injection accuracy.ObjectiveTo compare the effectiveness, adverse events, and the recurrence rate between ultrasound‐guided and palpation‐guided injection in patients with de Quervain disease.DesignProspective, single‐blind, randomized controlled trial.SettingRehabilitation department of a private teaching hospital.ParticipantsWe enrolled 49 patients, ≥20 years of age, clinically diagnosed with de Quervain disease based on their medical history and physical examination.InterventionsPatients were randomized into two groups: ultrasound‐guided and palpation‐guided injection. Both groups received a mixture of 10 mg triamcinolone acetonide (10 mg/1 mL) and 0.3 mL 1% lidocaine.Main Outcome MeasuresThe primary outcome measure was the Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH) score at 1 week. The secondary outcome measures were visual analog scale for pain (pain VAS) score, patient satisfaction, and adverse events or complications from the interventions at 1 week, 3 months, and 6 months.ResultsBoth groups showed improvement over time in QuickDASH scores and pain VAS (<jats:italic>p</jats:italic> &lt; .001); however, no statistically significant differences were noted between the groups for either QuickDASH scores (<jats:italic>p</jats:italic> = .22) or pain VAS (<jats:italic>p</jats:italic> = .30). In addition, no statistically significant differences were found between the groups in terms of patient satisfaction (<jats:italic>p</jats:italic> = .76) and adverse events (<jats:italic>p</jats:italic> = .47, .33, .58) at the 1‐week, 3‐month, and 6‐month follow‐ups.ConclusionsBoth ultrasound‐guided and palpation‐guided injections effectively treated de Quervain disease. During a 6‐month follow‐up, there were no statistically significant differences between the groups in pain relief, upper limb function, or patient satisfaction. However, the palpation‐guided group showed a tendency for more recurrence and skin side effects.","PeriodicalId":20287,"journal":{"name":"Pm & R","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ultrasound versus palpation‐guided corticosteroid injection for de Quervain disease: A randomized controlled trial\",\"authors\":\"Ying‐Chen Kuo, Lin‐Fen Hsieh, Ya‐Fang Liu, Chia‐Sung Chang\",\"doi\":\"10.1002/pmrj.13144\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"IntroductionCorticosteroid injection effectively treats de Quervain disease, and due to the high prevalence of the intracompartmental septum in the first extensor compartment, ultrasound guidance improves injection accuracy.ObjectiveTo compare the effectiveness, adverse events, and the recurrence rate between ultrasound‐guided and palpation‐guided injection in patients with de Quervain disease.DesignProspective, single‐blind, randomized controlled trial.SettingRehabilitation department of a private teaching hospital.ParticipantsWe enrolled 49 patients, ≥20 years of age, clinically diagnosed with de Quervain disease based on their medical history and physical examination.InterventionsPatients were randomized into two groups: ultrasound‐guided and palpation‐guided injection. Both groups received a mixture of 10 mg triamcinolone acetonide (10 mg/1 mL) and 0.3 mL 1% lidocaine.Main Outcome MeasuresThe primary outcome measure was the Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH) score at 1 week. The secondary outcome measures were visual analog scale for pain (pain VAS) score, patient satisfaction, and adverse events or complications from the interventions at 1 week, 3 months, and 6 months.ResultsBoth groups showed improvement over time in QuickDASH scores and pain VAS (<jats:italic>p</jats:italic> &lt; .001); however, no statistically significant differences were noted between the groups for either QuickDASH scores (<jats:italic>p</jats:italic> = .22) or pain VAS (<jats:italic>p</jats:italic> = .30). In addition, no statistically significant differences were found between the groups in terms of patient satisfaction (<jats:italic>p</jats:italic> = .76) and adverse events (<jats:italic>p</jats:italic> = .47, .33, .58) at the 1‐week, 3‐month, and 6‐month follow‐ups.ConclusionsBoth ultrasound‐guided and palpation‐guided injections effectively treated de Quervain disease. During a 6‐month follow‐up, there were no statistically significant differences between the groups in pain relief, upper limb function, or patient satisfaction. However, the palpation‐guided group showed a tendency for more recurrence and skin side effects.\",\"PeriodicalId\":20287,\"journal\":{\"name\":\"Pm & R\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pm & R\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/pmrj.13144\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pm & R","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/pmrj.13144","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

引言皮质类固醇注射能有效治疗德-夸尔曼病,由于第一伸肌室内隔的高发生率,超声引导能提高注射的准确性。设计前瞻性、单盲、随机对照试验.地点一家私立教学医院的康复科.参与者我们招募了49名患者,年龄≥20岁,根据病史和体格检查临床诊断为德-夸尔曼病.干预将患者随机分为两组:超声引导注射组和触诊引导注射组。两组均注射 10 毫克曲安奈德(10 毫克/1 毫升)和 0.3 毫升 1%利多卡因的混合物。主要结果测量主要结果测量为 1 周后的手臂、肩部和手部快速残疾(QuickDASH)评分。次要结果指标为 1 周、3 个月和 6 个月时的疼痛视觉模拟量表(疼痛 VAS)评分、患者满意度以及干预措施引起的不良事件或并发症。结果两组的 QuickDASH 评分和疼痛 VAS 均随时间推移有所改善(p < .001);但是,两组之间的 QuickDASH 评分(p = .22)或疼痛 VAS(p = .30)均无统计学意义上的显著差异。此外,在 1 周、3 个月和 6 个月的随访中,患者满意度(p = .76)和不良反应(p = .47、.33、.58)在组间也无统计学差异。在为期 6 个月的随访中,两组在疼痛缓解、上肢功能和患者满意度方面均无明显统计学差异。不过,触诊引导组的复发率和皮肤副作用较高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Ultrasound versus palpation‐guided corticosteroid injection for de Quervain disease: A randomized controlled trial
IntroductionCorticosteroid injection effectively treats de Quervain disease, and due to the high prevalence of the intracompartmental septum in the first extensor compartment, ultrasound guidance improves injection accuracy.ObjectiveTo compare the effectiveness, adverse events, and the recurrence rate between ultrasound‐guided and palpation‐guided injection in patients with de Quervain disease.DesignProspective, single‐blind, randomized controlled trial.SettingRehabilitation department of a private teaching hospital.ParticipantsWe enrolled 49 patients, ≥20 years of age, clinically diagnosed with de Quervain disease based on their medical history and physical examination.InterventionsPatients were randomized into two groups: ultrasound‐guided and palpation‐guided injection. Both groups received a mixture of 10 mg triamcinolone acetonide (10 mg/1 mL) and 0.3 mL 1% lidocaine.Main Outcome MeasuresThe primary outcome measure was the Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH) score at 1 week. The secondary outcome measures were visual analog scale for pain (pain VAS) score, patient satisfaction, and adverse events or complications from the interventions at 1 week, 3 months, and 6 months.ResultsBoth groups showed improvement over time in QuickDASH scores and pain VAS (p < .001); however, no statistically significant differences were noted between the groups for either QuickDASH scores (p = .22) or pain VAS (p = .30). In addition, no statistically significant differences were found between the groups in terms of patient satisfaction (p = .76) and adverse events (p = .47, .33, .58) at the 1‐week, 3‐month, and 6‐month follow‐ups.ConclusionsBoth ultrasound‐guided and palpation‐guided injections effectively treated de Quervain disease. During a 6‐month follow‐up, there were no statistically significant differences between the groups in pain relief, upper limb function, or patient satisfaction. However, the palpation‐guided group showed a tendency for more recurrence and skin side effects.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信